Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac 0.3% for Prevention of Pseudophakic Cystoid Macular Edema
NCT03025945Completed
- Sponsor
- Intuor Technologies
- Start
- Oct 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in pseudophakic cystoid macular edema (PCME) comparing Nepafenac 0.3% with Placebo (2 arms). Primary endpoint: Post-operative Clinical Findings of Cystoid Macular Edema at 6 weeks. Started Oct 2013; status: completed.
02
Drugs
nepafenac
03
Conditions
pseudophakic cystoid macular edema (PCME)
Beyond the preview
Go deeper on NCT03025945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03025945.